JD Health's 4Q Revenue Likely Lower Due to High Base -- Market Talk

Dow Jones01-19

0535 GMT - JD Health International's 4Q revenue will likely decline on year due to its high base although that will be partially offset by demand due to the recent flu outbreak, HSBC analysts say in a research note. JD Health's 4Q revenue could fall 7% on year, however, its 2023 revenue will likely grow 14%, the analysts say. They lift their top line estimates for 2023-2025 by 2% due to the strong growth in its health supplement category. They reckon that JD Health may also benefit from the introduction of social insurance reimbursement services online in several cities, including Shanghai. HSBC maintains its buy rating on JD Health and raises its target to HK$48.00 from HK$47.50. Shares were last 2.3% higher at HK$28.50. (sherry.qin@wsj.com)

(END) Dow Jones Newswires

January 19, 2024 00:35 ET (05:35 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2404543798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-19 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2404543798","market":"sg","top_or_hot":-1,"title":"JD Health's 4Q Revenue Likely Lower Due to High Base -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0535 GMT - JD Health International's 4Q revenue will likely decline on year due to its high base although that will be partially offset by demand due to the recent flu outbreak, HSBC analysts say in a research note. JD Health's 4Q revenue could fall 7% on year, however, its 2023 revenue will likely grow 14%, the analysts say. They lift their top line estimates for 2023-2025 by 2% due to the strong growth in its health supplement category. They reckon that JD Health may also benefit from the introduction of social insurance reimbursement services online in several cities, including Shanghai. HSBC maintains its buy rating on JD Health and raises its target to HK$48.00 from HK$47.50. Shares were last 2.3% higher at HK$28.50. (sherry.qin@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 19, 2024 00:35 ET (05:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health's 4Q Revenue Likely Lower Due to High Base -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health's 4Q Revenue Likely Lower Due to High Base -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-19 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0535 GMT - JD Health International's 4Q revenue will likely decline on year due to its high base although that will be partially offset by demand due to the recent flu outbreak, HSBC analysts say in a...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06618","symbol_name":"京东健康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2404543798","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404543798","pubTimestamp":1705642500,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0535 GMT - JD Health International's 4Q revenue will likely decline on year due to its high base although that will be partially offset by demand due to the recent flu outbreak, HSBC analysts say in a research note. JD Health's 4Q revenue could fall 7% on year, however, its 2023 revenue will likely grow 14%, the analysts say. They lift their top line estimates for 2023-2025 by 2% due to the strong growth in its health supplement category. They reckon that JD Health may also benefit from the introduction of social insurance reimbursement services online in several cities, including Shanghai. HSBC maintains its buy rating on JD Health and raises its target to HK$48.00 from HK$47.50. Shares were last 2.3% higher at HK$28.50. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"06618":"京东健康","JD":"京东"},"translate_title":"京东健康第四季度收入可能因基础市场高谈而下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JD":1,"06618":0.9},"content_text":"0535 GMT - JD Health International's 4Q revenue will likely decline on year due to its high base although that will be partially offset by demand due to the recent flu outbreak, HSBC analysts say in a research note. JD Health's 4Q revenue could fall 7% on year, however, its 2023 revenue will likely grow 14%, the analysts say. They lift their top line estimates for 2023-2025 by 2% due to the strong growth in its health supplement category. They reckon that JD Health may also benefit from the introduction of social insurance reimbursement services online in several cities, including Shanghai. HSBC maintains its buy rating on JD Health and raises its target to HK$48.00 from HK$47.50. Shares were last 2.3% higher at HK$28.50. (sherry.qin@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 19, 2024 00:35 ET (05:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404543798"}